Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences

View Full Paper

Ask AI

Bookmark

Why the study?

Does rivaroxaban improve treatment and prevent recurrences in patients with symptomatic venous thromboembolism compared to standard therapy?

Population

Patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism

Comparison

Rivaroxaban vs Standard therapy

Design

Review

Authors

Discussion

Rivaroxaban may be considered for VTE without monitoring; leaves open prospective validation in contemporary cohorts.

Does rivaroxaban improve treatment and prevent recurrences in patients with symptomatic venous thromboembolism compared to standard therapy?

Population

Patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism

Intervention

Rivaroxaban

Comparator

Standard therapy (parenteral or low-molecular-weight heparin for initial therapy and oral vitamin K antagonists for long-term therapy)

Rivaroxaban offers an effective and safer alternative to standard anticoagulation for VTE treatment, without the need for periodic monitoring.

Arcelus et al. (2014) studied this question.

View Full Paper

Ask AI

Bookmark